factitious hypoglycemia c peptide C-peptide is helpful to distinguish endogenous from exogenous insulin sources - What isfactitious hypoglycemia hypoglycemia Understanding Factitious Hypoglycemia: The Role of C-Peptide in Diagnosis

Factitious hypoglycemiavs insulinoma Factitious hypoglycemia is a serious medical condition characterized by recurrent episodes of low blood sugar that are intentionally self-induced.2025年8月6日—Factitious hypoglycemia, associated with insulin secretagogues, has been reported in multiple clinical scenarios, including medication errors ... Distinguishing this condition from other causes of hypoglycemia, such as insulinoma, can be challenging, but C-peptide measurements play a crucial role in accurate diagnosis. The interplay between plasma insulin and C-peptide immunoreactivity is key to understanding the underlying mechanisms and identifying factitious hypoglycemia.Factitious Hypoglycemia

What is C-peptide and why is it important?

C-peptide is a small protein fragment that is produced and released by the pancreas in equimolar amounts with insulin作者：TW Sheehy·1992·被引用次数：25—Plasma C-peptideand diagnosis of factitious hyperinsulinism. Study of an insulindependent diabetic patient with “spontaneous” hypoglycemia. Ann Intern Med .... When the pancreas produces insulin, it also produces C-peptide. Therefore, measuring C-peptide levels can help determine whether the insulin in a person's body is endogenous (produced by their own pancreas) or exogenous (administered from an external source, such as insulin injections). This distinction is critical in cases of factitious hypoglycemia.A Paradox Case with Recurrent Symptomatic Hypoglycemia

Factitious Hypoglycemia: The C-Peptide Connection

In individuals with factitious hypoglycemia caused by the surreptitious injection of insulin, laboratory tests performed during a hypoglycemic episode will typically reveal a specific biochemical profile作者：CM Waickus·1999·被引用次数：36—Insulin-induced hypoglycemia can be detected by aninsulin to C-peptide ratio that is greater than 1.0.. While hypoglycemia is present, there will be elevated levels of plasma insulin and, importantly, suppressed plasma C-peptide immunoreactivity. This is because the injected insulin does not trigger the pancreas to produce its own insulin, and thus, no C-peptide is released.

Conversely, in conditions like insulinoma, where a tumor in the pancreas overproduces insulin, both insulin and C-peptide levels will be elevated. This difference in c peptide levels is a cornerstone in differentiating between self-induced insulin use and endogenous insulin overproduction.

Diagnostic Indicators:

Several biochemical indicators are used to diagnose factitious hypoglycemia:

* Low C-peptide levels: The hallmark of exogenous insulin use is a low or undetectable C-peptide level in the presence of hypoglycemia and elevated insulin. This is because the body's own insulin production has been suppressed due to the external insulin administrationHowever, in patients withhypoglycemiaand elevatedc-peptidelevels, insulin levels above 100 mIU/mL are suggestive of sulfonylurea inducedhypoglycemiaas ....

* Insulin/C-peptide Ratio: A significantly elevated insulin/C-peptide ratio > 1 or an insulin to C-peptide ratio that is greater than 1.Factitious hypoglycemia in insulin-treated diabetic patients0 strongly suggests the administration of exogenous insulin. This ratio reflects the discrepancy between the amount of insulin present and the body's natural insulin production.

* Circulating Insulin Antibodies: In some cases, particularly with long-term self-injection of insulin, the presence of circulating insulin-binding antibodies can also be detected, further supporting the diagnosis of exogenous insulin administration.

* Plasma Insulin Levels: While high plasma insulin levels are expected in both factitious hypoglycemia and insulinoma, their combination with low C-peptide is the distinguishing factorFactitious Hypoglycemia: Diagnosis by Measurement of ....

The Role of C-Peptide Assay:

The C-peptide assay provides a valuable tool in the diagnosis of fasting hypoglycemia. This simple blood test can help clinicians differentiate between endogenous and exogenous causes of hypoglycemia. As highlighted in research from the NIH (National Institutes of Health), measurements of plasma insulin and C-peptide immunoreactivity have been instrumental in identifying factitious hypoglycemia.The validity ofC-peptidemeasurement in the diagnosis offactitious hypoglycemia. ...C-peptidefailed to show an increase. This combination is considered ... The diagnosis by measurement of serum C-peptide immunoreactivity is a well-established method.

Beyond Insulin: Sulfonylureas and C-Peptide

It's important to note that factitious hypoglycemia can also be induced by the surreptitious ingestion of certain medications, such as sulfonylureas. These drugs stimulate the pancreas to release insulin. In cases of sulfonylurea-induced hypoglycemia, both insulin and c peptide levels will be elevated. However, the pattern may differ from that seen in insulinoma, and specific tests can help identify the presence of sulfonylureas. Research on C-Peptide in Factitious Hypoglycemia from Sulfonylurea explores these diagnostic nuances.

Challenges in Diagnosis:

Diagnosing factitious hypoglycemia can be complex. Patients may go to great lengths to conceal their actions, leading to a diagnostic odyssey. The diagnosis by measurement of plasma insulin and C-peptide immunoreactivity is a critical step, but it often requires careful interpretation of results, especially when they are borderlineFactitious Hypoglycemia Caused by a Unique Pattern of .... A psychiatric evaluation may also be necessary, as factitious disorder is a rare but important condition to consider in the differential diagnosis of recurrent hypoglycemia.

Conclusion:

Understanding the intricate relationship between insulin and C-peptide is fundamental in unraveling the mystery of factitious hypoglycemia. The C-peptide measurement, alongside plasma insulin levels, offers a powerful diagnostic lens, helping clinicians distinguish self-induced hypoglycemia from other underlying medical conditionsA Paradox Case with Recurrent Symptomatic Hypoglycemia. Early and accurate diagnosis is crucial for effective management and intervention.作者：M Akbari·2017·被引用次数：11—The plasma levels of insulin andC-peptidecan help differentiate this condition from other causes (5). Overall, diagnosis is quite challenging, ... The c peptide is indeed a vital marker in the challenging landscape of hypoglycemia diagnosis, and C-peptide is helpful to distinguish endogenous from exogenous insulin sources.2009年3月26日—C-peptide is helpful to distinguish endogenous from exogenous insulin sources. Since insulin and C-peptide are secreted together in an equimolar ...